The Canadian Press on MSN2d
Health Canada approves Moderna's mRNA RSV vaccine, company says
Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Monthly Prescribing Reference10d
Drugs in the Pipeline
IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
Mena FN13d
Clover Announces Positive Clinical Data For RSV Vaccine Candidate SCB-1019 Compared Head-To-Head Versus GSK's AREXVY
"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...
pulmonologyadvisor14d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...
Juneau Empire15d
Border Patrol: Drawing the line between Alaska and Canada
His assignment was to help determine the boundary between Canada and the United States in order to clarify a treaty signed by Russia and Great Britain in 1825. While atop the mountain, he turned ...
Seeking Alpha16d
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...
Business Insider17d
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...
Sporting News17d
What is STRAUSS on MLB helmets? Explaining the controversial ads in 2024 World Series
Visible on every team's helmets during the playoffs is the word STRAUSS, accompanied by a small logo. In September, MLB announced a partnership with the brand to advertise on postseason gear for ...